A patient with stage III colon cancer was treated with hemicolectomy and FOLFOX. What is FOLFOX classified as?

FOLFOX is classified as multi-agent chemotherapy because it consists of a combination of multiple chemotherapy agents. Specifically, FOLFOX is a regimen that typically includes oxaliplatin, leucovorin, and 5-fluorouracil (5-FU). This multi-agent approach is designed to enhance the efficacy of treatment by targeting cancer cells in various ways, thereby increasing the likelihood of treatment success in patients with conditions such as stage III colon cancer.

In contrast to other forms of therapy, FOLFOX incorporates distinct mechanisms of action from its constituent drugs, making it more effective than the use of a single agent alone. This can result in better overall patient outcomes in terms of tumor response and progression-free survival. Single-agent chemotherapy would involve only one type of drug targeting the cancer, while hormone therapy and immunotherapy involve entirely different mechanisms of action that do not apply to FOLFOX's nature as a combination of chemotherapy agents.